STEVENSON, Md., March 4, 2014 (GLOBE NEWSWIRE) -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Immunomedics, Inc. ("Immunomedics" or the "Company") (Nasdaq:IMMU) common stock during the period between May 9, 2013 and October 9, 2013, inclusive (the "Class Period").
If you have suffered a net loss from investment in Immunomedics common stock purchased on or after May 9, 2013 and held through the revelation of negative information during and/or at the end of the Class Period, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff, at no cost to you, by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.
No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than April 28, 2014 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company units during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that, the Company and Takeda-Nycomed were embroiled in an on-going dispute regarding what Immunomedics considered to be an unacceptable delay in the development of Veltuzumab in violation of a License and Collaboration Agreement ("Agreement") with Nycomed GmbH ("Nycomed"), whereby the Company issued Nycomed a worldwide license to develop, manufacture and commercialize one of its most advanced therapeutic compounds, Veltuzumab. According to the complaint, following the Company's October 9, 2013 announcement that the Agreement had been terminated, the value of Immunomedics shares declined significantly.
If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.